Harpoon Therapeutics

Harpoon Therapeutics

Pharmaceutical Manufacturing

South San Francisco, California 13,172 followers

SPEARHEADING IMMUNOTHERAPIES

About us

Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon’s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome. For more information, please visit www.harpoontx.com.

Industry
Pharmaceutical Manufacturing
Company size
51-200 employees
Headquarters
South San Francisco, California
Type
Public Company
Founded
2015

Locations

  • Primary

    611 Gateway Blvd.

    Suite 400

    South San Francisco, California 94080, US

    Get directions

Employees at Harpoon Therapeutics

Updates

Affiliated pages

Similar pages

Browse jobs

Funding

Harpoon Therapeutics 5 total rounds

Last Round

Post IPO equity

US$ 100.0M

See more info on crunchbase